程序性死亡受体1/程序性死亡受体配体1抑制剂联合抗血管生成药物治疗晚期肝细胞癌的临床研究进展

Progress of Clinical Studies on Programmed Death-1/Programmed Death-Ligand 1 Inhibitors Combined with Angiogenesis Inhibitors in the Treatment of Advanced Hepatocellular Carcinoma

靶免联合治疗在晚期肝细胞癌中发挥着越来越重要的作用,其中程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂联合抗血管生成药物治疗晚期肝细胞患者具有良好的疗效和可接受的毒性。抗血管生成药物不仅可以使肿瘤血管系统正常化,还可以介导免疫微环境,增强PD-1/PD-L1抑制剂的疗效。本文总结了PD-1/PD-L1抑制剂联合抗血管生成药物治疗晚期肝细胞癌的一线治疗方案,概述联合治疗的作用机制,回顾和分析这些一线治疗方案的临床研究以及差异性,并对其真实世界研究进行探讨,为后续晚期肝细胞癌的治疗策略提供新的方向和思路。

Targeted therapy combined with immunotherapy is playing an increasingly important role in advanced hepatocellular carcinoma,in which programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors combined with angiogenesis inhibitors have significant efficacy and acceptable toxicity in patients with advanced hepatocytes.Angiogenesis inhibitors can not only normalize the tumor vascular system,but mediate the immune microenvironment and enhance the efficacy of PD-1/PD-L1 inhibitors.This paper summarizes the first-line treatment of advanced hepatocellular carcinoma with PD-1/PD-L1 inhibitors combined with angiogenesis inhibitors,generalizes the mechanism of action of the combined treatment,reviews and analyzes the clinical studies and differences of these first-line treatment regimens,and discusses the real-world studies,so as to provide a new direction and idea for the subsequent treatment strategy of advanced hepatocellular carcinoma.